Effectiveness of Credelio® Plus, a novel chewable tablet containing milbemycin oxime and lotilaner for the treatment of larval and immature adult stages of Toxocara canis in experimentally infected dogs

Table 1 Effectiveness of a single oral dose of a novel chewable tablet (Credelio Plus) containing milbemycin oxime and lotilaner against induced L4 larval and immature adult [L5] Toxocara canis infections in dogs

Study	Stage at time of treatment	Day of inoculation^a	Day of treatment	Day of necropsy (worm recovery)	Treatment group	n	No. of infected dogs	Worm count range	Geometric worm count	Effectiveness compared to vehicle control
Study	Stage at time of treatment	Day of inoculation^a	Day of treatment	Day of necropsy (worm recovery)	Treatment group	n	No. of infected dogs	Worm count range	Geometric worm count	% efficacy	Effectiveness P-value
1	L4 larvae	0	14	19	Vehicle control	10	7	0–20	4.8	–	–
					Credelio Plus^b	10	0	0–0	0	100	< 0.001
2	L4 larvae	0	14	20	Vehicle control	10	10	2–51	9.9	–	–
					Credelio Plus^b	10	3	0–3	0.3	96.8	< 0.001
1	Immature adult [L5]	0	24	30	Vehicle control	10	10	4–72	22.1	–	–
					Credelio Plus ^b	10	4	0–1	.3	98.6	< 0.001
2	Immature adult [L5]	0	24	30	Vehicle control	10	10	5–67	22.3	–	–
					Credelio Plus ^b	10	4	0–2	0.4	98.3	< 0.001

n number of animals per group
^aEach dog was inoculated with ca. 250 infective T. canis eggs
^bCredelio Plus provided minimum dosages of 0.89 to 1.0 mg/kg of milbemycin oxime in both studies

ISSN: 1756-3305